The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

Eli Lilly has been rapidly expanding a new website that connects patients with telehealth providers specialized in certain conditions it also sells drugs for, such as diabetes, obesity ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...